← All Drugs

Propranolol

Inderal · Hemangeol

Beta-Adrenergic BlockerGeneric available

Mechanism of Action The mechanism of the antihypertensive effect of propranolol has not been established. Among the factors that may be involved in contributing to the antihypertensive action include: (1) decreased cardiac output, (2) inhibition of renin release by the kidneys, and (3) diminution of tonic sympathetic nerve outflow from vasomotor centers in the brain. Although total peripheral resistance may increase initially, it readjusts to or below the pretreatment level with chronic use of propranolol. Effects of propranolol on plasma volume appear to be minor and somewhat variable. In angina pectoris, propranolol generally reduces the oxygen requirement of the heart at any given level of effort by blocking the catecholamine-induced increases in the heart rate, systolic blood pressure, and the velocity and extent of myocardial contraction. Propranolol may increase oxygen requirements by increasing left ventricular fiber length, end diastolic pressure, and systolic ejection period. The net physiologic effect of beta-adrenergic blockade is usually advantageous and is manifested during exercise by delayed onset of pain and increased work capacity. Propranolol exerts its antiarrhythmic effects in concentrations associated with beta-adrenergic blockade, and this appears to be its principal antiarrhythmic mechanism of action. In dosages greater than required for beta blockade, propranolol also exerts a quinidine-like or anesthetic-like membrane action which affects the cardiac action potential. The significance of the membrane action in the treatment of arrhythmias is uncertain. The mechanism of the anti-migraine effect of propranolol has not been established. Beta-adrenergic receptors have been demonstrated in the pial vessels of the brain.

Compare Propranolol

FDA-Approved Indications

  • Hypertension (adults)
  • Angina pectoris (adults)
  • Migraine prophylaxis (adults)
  • Hypertrophic subaortic stenosis (adults)
  • Essential tremor (adults)
  • Cardiac arrhythmias (adults)
  • Post-MI mortality reduction (adults)
  • Pheochromocytoma — adjunct (adults)

Common Off-Label Uses

  • Performance anxiety
  • PTSD
  • Akathisia
  • Lithium-induced tremor
  • Aggressive behavior
  • Infantile hemangioma

What Sets This Drug Apart

  • Non-selective beta-blocker with CNS penetration; no FDA psychiatric indication but widely used off-label for performance anxiety (stage fright, public speaking)
  • Targets peripheral autonomic symptoms of anxiety (tremor, tachycardia, sweating) rather than cognitive anxiety — mechanism fundamentally different from benzodiazepines
  • NOT effective for panic disorder or GAD as monotherapy — treats somatic symptoms only, not the underlying anxiety disorder
  • Emerging evidence for antipsychotic-induced akathisia (off-label); reasonable adjunct when beta-blockers are not contraindicated
  • Multiple CYP substrate (2D6, 1A2, 2C19); contraindicated in asthma, severe bradycardia, heart block, and decompensated heart failure
Boxed Warning
Angina Pectoris There have been reports of exacerbation of angina and, in some cases, myocardial infarction, following abrupt discontinuance